Pure BoNT/E1 complex was purchased from WAKO Chemicals. affinity and maintain cross-serotype reactivity for the 4E17 mAb. Both 1B18 and 4E17 bound to a relatively conserved epitope at the tip of the BoNT translocation domain name. Immunoglobulin G constructed from affinity matured variants mAChR-IN-1 hydrochloride of 1B18 and 4E17 were evaluated for their ability to neutralize BoNT/B and E, respectively, Both antibodies potently neutralized BoNT demonstrating that this epitope is usually functionally important in the intoxication pathway. Such cross-serotype binding and neutralizing mAbs should simplify the development of antibody-based BoNT diagnostics and therapeutics. Keywords: botulism, botulinum neurotoxin, molecular evolution, single-chain Fv, yeast display Introduction Botulism is caused by botulinum neurotoxin (BoNT; Centers for Disease Control, 1998) the most poisonous material known (Gill, 1982). The crystal structure of BoNTs (Lacy and bound nearly identical conserved epitopes at the tip of the BoNT HN. The results demonstrate that useful mAbs binding multiple BoNT serotypes, while rare, do exist and suggest an important functional role for the tip of the HN. Results Identification and initial characterization of cross-reactive BoNT mAbs To identify mAbs binding multiple BoNT serotypes, we studied a panel of 35 antibodies binding BoNT/A, B or E (Supplementary Table S1). Thirty three mAbs were generated from humans immunized with an investigational vaccine made up of BoNT/A, B, C, D and E (pentavalent botulinum toxoid), and two mAbs were generated from a mouse immunized with BoNT/A mAChR-IN-1 hydrochloride holotoxin (S25 and C25). All mAbs were isolated from single-chain variable fragment (scFv) gene libraries generated from immune B-cells and displayed on either the surface of phage or the surface of yeast (Amersdorfer BoNT neutralization studies, it is either necessary or desirable to utilize immunoglobulin G (IgG; Nowakowski = 5.83) and BoNT/E (no Mouse monoclonal to PR binding observed; Table?IV and Fig.?5). Unlike for 1B18 binding to BoNT/B, no other alanine mutation resulted in a >1.0 for 4E17.1 binding to either BoNT/A or E. Alignment of the X-ray crystal structures of BoNT/A, B and E at the epitope indicates that there are both significant similarities and differences in the epitope structures (Fig.?6). All three epitopes are located at the tip of mAChR-IN-1 hydrochloride the HN, consistent with images of 4E17.1 binding to BoNT/E obtained by single particle electron microscopy (Fischer of alanine-substituted BoNT HN mutants = RTln(values from Table?IV. The lower set of panels show the side chains of amino acids E755, E756 and E757 of BoNT/A and their corresponding amino acids in BoNT/B and E around the aligned crystal structures. Potency of in vivo BoNT neutralization by mAbs 2B18.1 and 4E17.1 Given the conservation of 1B18/4E17 binding across serotypes and subtypes, we wondered whether the epitope was associated with biology relevant to intoxication. To evaluate this, we compared the potency of BoNT/B and E neutralization by mAbs 2B18.1 and 4E17.1, respectively, to the non-neutralizing BoNT/B mAb B6.1 (Lou DH5 was used for cloning and preparation of plasmid DNA. Pure BoNT types A1, A2, B1, E3 and proteolytic F Langeland were purchased from Metabiologics. Pure BoNT/E1 complex was purchased from WAKO Chemicals. Pure BoNT/A3, B2, bivalent B3 and non-proteolytic B4 were purified from their respective strains. Crude BoNT/E2 was prepared from CDC 5247 and was used unpurified. SV5 antibody was purified from hybridoma supernatant using Protein G and directly labeled with Alexa-488 or Alexa-647 using a kit provided by the manufacturer (Molecular Probes). Initial characterization of a panel of BoNT antibodies A panel of 35 scFvs binding BoNT/A, B or E were studied. Thirty-three mAbs were generated from humans immunized with pentavalent botulinum toxoid, and two mAbs were generated from a mouse immunized with BoNT/A holotoxin (S25 and C25). All mAbs were isolated from scFv gene libraries generated from immune B-cells.
